Research ArticlePsoriasis

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

See allHide authors and affiliations

Science Translational Medicine  11 Oct 2017:
Vol. 9, Issue 411, eaan2514
DOI: 10.1126/scitranslmed.aan2514

Article Information

vol. 9 no. 411

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 17, 2017
  • Resubmitted June 16, 2017
  • Accepted for publication August 21, 2017

Author Information

  1. Satveer K. Mahil1,
  2. Marika Catapano1,2,
  3. Paola Di Meglio1,3,
  4. Nick Dand1,
  5. Helena Ahlfors4,
  6. Ian M. Carr5,
  7. Catherine H. Smith1,
  8. Richard C. Trembath1,
  9. Mark Peakman6,
  10. John Wright7,
  11. Francesca D. Ciccarelli2,8,*,
  12. Jonathan N. Barker1,* and
  13. Francesca Capon1,
  1. 1Division of Genetics and Molecular Medicine, King’s College London, London SE1 9RT, UK.
  2. 2Cancer Systems Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  3. 3AhRimmunity Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  4. 4UCL Institute of Child Health, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.
  5. 5School of Medicine, University of Leeds, Leeds, LS9 7TF, UK.
  6. 6Department of Immunobiology, King’s College London, London SE1 9RT, UK.
  7. 7Bradford Royal Infirmary, Bradford Institute for Health Research, Bradford BD9 6RJ, UK.
  8. 8Division of Cancer Studies, King’s College London, London SE1 1UL, UK.
  1. Corresponding author. Email: francesca.capon{at}kcl.ac.uk
    • * These authors contributed equally to this work.

    AltMetrics

    Article usage

    AbstractFullPDF
    Oct 20174926260441